MOLOGEN AG
MOLOGEN AG: Oliver Krautscheid reelected as Chairman of the Supervisory Board (news with additional features)
MOLOGEN AG / Key word(s): AGM/EGM PRESS RELEASE N 12 / 2015 of 07/30/2015 MOLOGEN AG: Oliver Krautscheid reelected as Chairman of the Supervisory Board Berlin, July 30, 2015 – At yesterday’s Annual General Meeting of the biotechnology company MOLOGEN AG, Oliver Krautscheid was reelected as a member of the Supervisory Board. In addition, the Supervisory Board once again unanimously voted Oliver Krautscheid to the position of Chairman of the Supervisory Board. Stefan M. Manth, MD, will remain in the role of Vice Chairman. The shareholders also approved the main items on the agenda. The voting results and further information on the Annual General Meeting can be found on the company website under: MOLOGEN AG The cancer immunotherapy MGN1703 is the company’s lead product and best-in-class TLR9 agonist. It is currently developed for first-line maintenance treatment of colorectal cancer (pivotal randomized trial) and small cell lung cancer (randomized controlled trial). A second clinical-stage product is MGN1601, a therapeutic vaccination for the treatment of renal cancer. A phase I/II clinical study has already been completed successfully. For more information on the trials please visit www.clinicaltrials.gov. With unique, patented technologies and innovative products, MOLOGEN is pioneering immuno- therapies. MOLOGEN AG is a publicly listed company, headquartered in Berlin. The shares (ISIN DE0006637200) are listed in the Prime Standard of the German Stock Exchange. www.mologen.com MIDGE(R), dSLIM(R), EnanDIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG. Contact Note about risk for future predictions
+++++ Additional features: Document: http://n.equitystory.com/c/fncls.ssp?u=HYUSYIOLIJ Document title: MOLOGEN AG: Oliver Krautscheid reelected as Chairman of the Supervisory Board 2015-07-30 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
Language: | English | |
Company: | MOLOGEN AG | |
Fabeckstraße 30 | ||
14195 Berlin | ||
Germany | ||
Phone: | 030 / 841788-0 | |
Fax: | 030 / 841788-50 | |
E-mail: | presse@mologen.com | |
Internet: | www.mologen.com | |
ISIN: | DE0006637200 | |
WKN: | 663720 | |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart | |
End of News | DGAP News-Service |
382487 2015-07-30 |